Jun 11, 2026 07:02AM
May 28, 2026 07:04AM
May 13, 2026 04:59PM
May 12, 2026 04:08PM
Apr 8, 2026 06:39AM
Mar 24, 2026 03:59AM
Mar 20, 2026 06:37AM Relmada Therapeutics Inc (RLMD) PT Raised to $19 at Mizuho
Mar 19, 2026 04:10PM
Mar 13, 2026 02:49PM
Mar 9, 2026 08:31AM
Mar 2, 2026 06:05AM
Jan 23, 2026 06:20AM
Jan 12, 2026 07:02AM
Dec 23, 2025 10:00AM Why Jefferies sees these stocks as standout biotech plays in 2026
Dec 22, 2025 12:49AM
Dec 21, 2025 08:00PM
Nov 19, 2025 04:02AM
Nov 13, 2025 04:31PM
Sep 16, 2025 11:20AM
Sep 16, 2025 11:20AM
Sep 16, 2025 11:20AM Sidoti Events, LLC's Virtual September Small-Cap Conference
Sep 16, 2025 11:20AM
Sep 10, 2025 07:15AM
Aug 7, 2025 04:22PM
Jul 15, 2025 08:02AM
May 12, 2025 04:04PM
Apr 28, 2025 01:39PM
Mar 26, 2025 05:59AM Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD)
Mar 25, 2025 07:32AM
Feb 6, 2025 03:18PM
Feb 6, 2025 07:30AM
Dec 9, 2024 07:31AM
Dec 5, 2024 02:59AM
Dec 4, 2024 12:15PM
Dec 4, 2024 07:30AM Relmada Therapeutics (RLMD) Reports That Data Monitoring Committee Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficac
Nov 14, 2024 07:31AM
Nov 7, 2024 04:34PM
Sep 17, 2024 04:01AM
Sep 12, 2024 07:54AM
Aug 30, 2024 04:25PM
Aug 7, 2024 04:22PM
Jun 18, 2024 08:31AM Relmada Therapeutics (RLMD) Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017

415,277 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All